1Murata Y, Nannmark U, Rydevik B, et al. Nucleus pulposus - induced apoptosis in dorsal root ganglion following experimental disc herniation in rats[ J]. Spine ,2006,4:382 - 390.
2Murata Y, Nanmnark U, Rydevik B, et al. The role of tumor necrosis factor - alpha in apoptosis of dorsal root ganglion cells induced by herniated nucleus pulposus in rats[J]. Spine,2008,2:155 -162.
3Otoshi K, Kikuchi S, Konno S,et al. The reactions of glial cells and endoneurial macrophages in the dorsal root ganglion and their contribution to pain - related behavior after application of nucleus pulposus onto the nerve root in rats [ J ]. Spine,2010,3:264 - 271.
4Shamji MF, Jing L, Chen J, et al. Treatment of neuroinflammation by soluble tumor necrosis factor receptor type II fused to a thermally responsive carrier[ J]. J Neurosurg Spine,2008,2:221 -228.
5Zhang KB, Zheng ZM, Liu H, et al. The effects of punctured nucleus pulposus on lumbar radieular pain in rats:a behavioral and immunohistochemical study [ J ]. J Neurosurg Spine, 2009,4:492 - 500.
6Genevay S, Finckh A, Payer M ,et al. Elevated levels of tumor necrosis factor - alpha in periradicular fat tissue in patients with radiculopathy from herniated disc[ J]. Spine,2008,19:2041 - 2046,.
7Yamashita M, Ohtori S, Koshi T,et al. Tumor necrosis factor- alpha in the nucleus pulposus mediates radicular pain, but not increase of in flammatory peptide, associated with nerve damage in mice[ J ]. Spine, 2008,17:1836 - 1842.
8Yoshida T,Park JS, Yokosuka K ,et al. Effect of a nonprotein bioactive agent on the reduction of cyclooxygenase - 2 and tumor necrosis factor -alpha in human intervertebral disc cells in vitro [ J]. J Neurosurg Spine,2008,5:411 -418.
9Suzuki M, lnouc G, Gemba T,et al. Nuclear factor- kappa B decoy suppresses nerve injury and improves mechanical allodynia and thermal hyperalgesia in a rat lumbar disc herniation model[ J]. Eur Spine J ,2009,7 : 1001 - 1007.
10Aydin MV, Sen O, Kayaselcuk F,et al. Analysis and prevalence of inflammatory cells in subtypes of lumbar disc herniations under cyclooxygenase - 2 inhibitor therapy [ J]. N eurol Res, 2005,6 : 609 - 612.
